Medpace (MEDP) stock: Q2 2026 results, buy or not?

2026-07-23 · By Lubin Danilo, founder of Lubin Investment

Medpace Holdings: see the full analysis on Lubin Investment

Medpace delivered a very strong second quarter of 2026: revenue up 17 %, earnings above expectations, full-year guidance raised, and the stock jumped nearly 19 % on the news. It is one of the most profitable businesses I follow. But after that pop, it is no longer really undervalued: high quality, yes, cheap, not so much anymore.

What Medpace announced on July 22, 2026

Medpace reported its second-quarter 2026 results on July 22, and they are solid across the board. Revenue reached 707.3 million dollars, up 17.2 % year over year, above the 690 million analysts expected. Earnings per share came in at 4.25 dollars, versus roughly 4.00 dollars expected. This is not a "fine" quarter: it is a clear beat, on both the top and the bottom line.

The most telling part is profitability. Net margin, the share of every dollar of sales that ends up as profit, rose from 15.0 % a year ago to 17.2 % this quarter. The company now earns more on each dollar it collects than it did twelve months ago: the mark of a business getting more efficient as it grows, what we call operating leverage. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, a measure of raw operating profitability) climbed to 153.4 million.

Above all, Medpace raised its full-year 2026 guidance: the revenue midpoint moved to roughly 2.85 billion dollars (from 2.81 before), and the earnings-per-share midpoint to about 17.60 dollars. A management team that raises guidance mid-year is telling you it sees demand improving, not fading. The market got the message: the stock jumped 18.6 % that day, to nearly 626 dollars.

Metric	Q2 2026	Reference
Revenue	$707.3M	+17.2 % year over year
Earnings per share (GAAP)	$4.25	above the ~$4.00 expected
Net margin	17.2 %	vs 15.0 % a year earlier
Book-to-bill	1.13x	above 1 = growing backlog
2026 EPS guidance	~$17.60 (raised)	vs ~$2.81B revenue before
Stock reaction	+18.6 % to ~$626	on July 22

Book-to-bill, the number I look at before anything else

To understand Medpace, you first have to understand what it does. Medpace is a CRO (contract research organization): when a pharma company or a biotech has a molecule to test, it hands Medpace the job of running its clinical trials, from patient recruitment to regulatory submission. I detailed that model and its durable edge in my full thesis on the stock; here, I focus on what this quarter changes.

The single most important number for a CRO is not quarterly revenue: it is book-to-bill. That is the ratio of new business signed during the period to revenue billed over the same period. Above 1, the company signs more future work than it delivers: its backlog grows, so its revenue for the coming quarters is already largely visible. Below 1, the backlog shrinks. This quarter, Medpace posted a book-to-bill of 1.13x, with 795.7 million dollars of net new business awards.

Why does it matter so much? Because that figure had been watched with anxiety for over a year. A book-to-bill clearly above 1 signals that demand for clinical trials is picking up again, after a stretch when the market feared a slowdown. It is this rebound in order intake, even more than the quarter's earnings, that explains the stock's enthusiasm.

A reminder: why Medpace is a rare-quality business

My method always judges a business's quality separately from its price: they are two different questions, and a great company bought too expensively is still a bad investment. On quality, Medpace ticks almost every box. Over the last five years, revenue has grown by about 21 % a year, and free cash flow per share (the money genuinely available to each shareholder once every bill and investment is paid) by roughly 35 % a year. That is not ordinary growth.

Two traits stand out to me. First, Medpace carries no net debt: it holds about 650 million dollars of net cash, so there is zero balance-sheet risk. Second, it buys back its own shares aggressively: the share count has fallen by more than 24 % in five years. Each remaining shareholder mechanically owns a growing slice of the company, doing nothing. A free-cash-flow margin of nearly 26 % over twelve months rounds out the picture: out of 100 dollars of sales, about 26 end up as real cash.

One honest caveat, though: this particular quarter, the free-cash-flow margin dropped to 19.5 %, from 23.6 % a year earlier. That is not a deterioration of the business, it is cash timing: a CRO incurs trial costs before billing certain milestones to its clients, so cash comes in unevenly from quarter to quarter. It is in fact the only one of my criteria where Medpace gets a mere warning rather than a full pass: its cash-collection cycle is stable but not improving.

The real risk, often underestimated

Medpace's main risk lies in the nature of its clients. A large part of its business comes from small and mid-sized biotechs, whose clinical-trial budgets depend directly on their ability to raise money: IPOs, venture capital, financial markets. When money floods into biotech, orders pour in. When funding dries up, biotechs cut or delay their trials, and Medpace's orders slow down.

That is exactly the cycle that worried the market over recent quarters, and it is why the book-to-bill rebound to 1.13x matters so much: it suggests the tough phase is easing. But keep it in mind: Medpace is an excellent business exposed to a factor it does not control, investors' appetite for biotech risk. A good quarter does not remove that risk, it pauses it.

The price: quality, yes, but the bargain has flown away

That leaves the question of price. To measure it, I use P/FCF (price to free cash flow): the share price relative to the cash the company actually generates each year. A P/FCF of 22 means you are paying today the equivalent of twenty-two years of that cash. The lower it is, the cheaper the stock. Medpace is valued at around 22 times its free cash flow.

A multiple says nothing on its own: you have to place it within the stock's own history. At 22 times, Medpace sits roughly at the 49th percentile of its own historical range, right in the middle: neither cheap nor expensive, by its standards. Before the release, the stock traded a notch below my fair value, around 657 dollars. The 18.6 % jump to nearly 626 dollars closed most of that gap.

Is it justified? For a machine compounding revenue at 20 % a year, with no debt and heavy buybacks, a P/FCF in the low 20s is not excessive: quality deserves a premium. But let's be clear: after this pop, the margin of safety is thin, around 5 %. So my verdict is nuanced. Medpace remains a company I would love to own, and this quarter confirms its trajectory. It is simply no longer the bargain it was a few weeks ago: I would wait for a pullback to start a new position rather than chase the rebound.

You can find the full criteria, the valuation and up-to-date data on Medpace's page, and see how the same grid applies to another quality healthcare name like DexCom. My way of analyzing never changes: quality first, price second, and never the other way around.

Verdict: an exceptional business, excellent Q2 2026 results, but a valuation that is stretched again after the near-19 % pop.
Revenue up 17.2 %, earnings above expectations, 2026 full-year guidance raised.
Book-to-bill of 1.13x: demand for clinical trials is picking up, the real driver of the stock's jump.
Rare quality: net cash, high margins, buybacks (more than 24 % fewer shares in five years).
The risk to watch: dependence on biotech funding, a cyclical factor outside Medpace's control.
At nearly $626, the discount has mostly gone: I would wait for a pullback to buy fresh.

FAQ

Should you buy Medpace stock after its Q2 2026 results?

The business is of rare quality and the quarter confirms its trajectory, but after a near-19 % jump the stock trades around the middle of its historical range and leaves only a thin margin of safety. Verdict: hold if you own it, but I would wait for a pullback to start a new position. This is not investment advice.

Why did Medpace stock jump nearly 19 %?

Three reasons: revenue and earnings above expectations, a raise to 2026 guidance, and above all a book-to-bill of 1.13x signalling that order intake is picking up again after a period of worry about demand.

What is book-to-bill?

It is the ratio of new business signed during a period to revenue billed over the same period. Above 1, the company books more future work than it delivers: its backlog grows, so its coming revenue is already largely visible. It is the most important leading indicator for a CRO.

What is Medpace's main risk?

Dependence on biotech funding cycles. A large part of its clients are small and mid-sized biotechs whose trial budgets depend on their ability to raise money. If capital dries up, orders slow. It is a cyclical risk Medpace does not control.

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).